| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-15-1527 |
| P698 | PubMed publication ID | 26819453 |
| P50 | author | Carl H. June | Q19277113 |
| Saad S. Kenderian | Q45896559 | ||
| Marco Ruella | Q56947896 | ||
| Simon F Lacey | Q56978267 | ||
| Mariusz A Wasik | Q87224772 | ||
| P2093 | author name string | Michael Milone | |
| Qian Zhang | |||
| Marcela V Maus | |||
| Stephen J Schuster | |||
| Michael Klichinsky | |||
| Olga Shestova | |||
| Selene Nunez-Cruz | |||
| Xiaobin Liu | |||
| Saar Gill | |||
| Omkar U Kawalekar | |||
| Sohail Qayyum | |||
| Michael Kalos | |||
| Joseph A Fraietta | |||
| Anthony Mato | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ibrutinib | Q5984881 |
| P304 | page(s) | 2684-2696 | |
| P577 | publication date | 2016-01-27 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma | |
| P478 | volume | 22 |
| Q64120024 | A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy |
| Q55292778 | Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? |
| Q93039755 | Advances and Challenges of CAR T Cells in Clinical Trials |
| Q92911767 | Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia |
| Q45871879 | Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse. |
| Q92401522 | Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib |
| Q99730742 | CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? |
| Q38957129 | Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse |
| Q38913549 | Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You. |
| Q38600697 | Chimeric antigen receptor T-cell therapies for lymphoma |
| Q55443158 | Chimeric antigen receptor T‑cell therapy—a hematological success story. |
| Q42654456 | Clinical trials of CAR-T cells in China |
| Q45870279 | Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy |
| Q39044162 | Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now? |
| Q55438228 | Cytokine release syndrome. |
| Q52715364 | Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. |
| Q91969134 | Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors |
| Q89032225 | Driving cars to the clinic for solid tumors |
| Q92026848 | Drug therapy for double-hit lymphoma |
| Q30827633 | Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies |
| Q92110272 | Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma Cells |
| Q90334543 | Emerging Cellular Therapies for Cancer |
| Q59793942 | FLT3 inhibitors in acute myeloid leukemia |
| Q92156519 | Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL |
| Q64274976 | Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas |
| Q90466623 | Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma |
| Q37528067 | Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. |
| Q42909982 | Ibrutinib treatment improves T cell number and function in CLL patients |
| Q48556375 | Immune Checkpoint Blockade in Breast Cancer Therapy |
| Q42375194 | Incorporation of functional elements enhances the antitumor capacity of CAR T cells |
| Q57059973 | Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell |
| Q51455494 | Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. |
| Q90436838 | Mechanisms of failure of chimeric antigen receptor T-cell therapy |
| Q90319400 | Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape |
| Q40314122 | Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia |
| Q50581082 | Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. |
| Q93240079 | PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression |
| Q38789518 | Recent advances in T-cell immunotherapy for haematological malignancies |
| Q49888075 | Role of Bruton's tyrosine kinase in B cells and malignancies |
| Q92199213 | Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma |
| Q88908601 | Spontaneous regression of mantle cell lymphoma: a report of four cases |
| Q38654101 | Targeting B Cell Signaling in Chronic Lymphocytic Leukemia |
| Q89524411 | The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity |
| Q92905230 | Tumor Metabolism as a Regulator of Tumor-Host Interactions in the B-Cell Lymphoma Microenvironment-Fueling Progression and Novel Brakes for Therapy |
| Q64949581 | Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. |
Search more.